Moldow B, Sander B, Larsen M, Engler C, Li B, Rosenberg T, Lund-Andersen H
University of Copenhagen, Herlev Sygehus, Department of Ophthalmology, Denmark.
Graefes Arch Clin Exp Ophthalmol. 1998 Dec;236(12):881-9. doi: 10.1007/s004170050175.
The carbonic anhydrase inhibitor acetazolamide (AZM) reduces macular oedema in some patients with retinitis pigmentosa. To better understand the oedema-reducing effect of AZM, the effect of AZM on passive permeability and active transport of fluorescein across the blood-retina barrier was studied in patients with retinitis pigmentosa and varying degrees of macular oedema.
The selection of patients was based on an introductory examination including vitreous fluorometry for qualitative assessment of the vitreous. Macular oedema was graded by fluorescein angiographic leakage. The effect of AZM on the transport properties of the blood-retina barrier was determined by differential spectrofluorometry, in a randomised, double-masked, cross-over study, comprising 2 weeks' treatment with AZM (500 mg/day) and 2 weeks' treatment with placebo. The penetration ratio, defined as the ratio between vitreous concentration 3 mm in front of the retina and the plasma integral, was determined for fluorescein and its metabolite fluorescein glucuronide at 30-60 min and at 120 min after fluorescein injection. Passive permeability and unidirectional permeability in the direction vitreous to blood, due to outward active transport of fluorescein, were determined in those cases where the curves for vitreous concentration of fluorescein could be fitted to a mathematical model. Visual acuity was tested by use of ETDRS standard logarithmic charts.
Twenty-two patients volunteered to participate in the study. Signs of significant vitreous detachment/liquefaction caused the exclusion of ten patients after the introductory examination. Nine patients with approximately intact vitreous and varying degrees of oedema completed the cross-over study. AZM treatment was related to a decrease in the penetration ratio of 21% for fluorescein (P=0.01) and of 22% for fluorescein glucuronide (P=0.004). Passive permeability and unidirectional permeability were determined in seven patients. AZM caused a decrease of 27% in the passive permeability of fluorescein (from 1.1 x 10(1) nm/s, P=0.031), and a 95% increase in unidirectional permeability of fluorescein (from 1.2 x 10(2) nm/s, P=0.047). AZM led to a reduction in the grade of macular oedema as determined by fluorescein angiography in three out of seven patients. Only small improvements (< or =5 letters) in visual acuity were noted.
The present study indicates that the oedema-reducing effect of AZM is due to decreased leakage and stimulated active transport across the blood-retina barrier.
碳酸酐酶抑制剂乙酰唑胺(AZM)可减轻部分色素性视网膜炎患者的黄斑水肿。为更好地理解AZM减轻水肿的作用机制,我们研究了AZM对色素性视网膜炎及不同程度黄斑水肿患者荧光素跨血视网膜屏障被动通透性和主动转运的影响。
患者的选择基于初步检查,包括玻璃体荧光测定法以定性评估玻璃体。黄斑水肿通过荧光素血管造影渗漏分级。在一项随机、双盲、交叉研究中,采用差示荧光分光光度法测定AZM对血视网膜屏障转运特性的影响,该研究包括2周的AZM(500毫克/天)治疗和2周的安慰剂治疗。在荧光素注射后30 - 60分钟及120分钟时,测定荧光素及其代谢产物荧光素葡糖醛酸的渗透比,渗透比定义为视网膜前3毫米处玻璃体浓度与血浆积分的比值。在荧光素玻璃体浓度曲线可拟合数学模型的情况下,测定荧光素从玻璃体到血液方向的被动通透性和单向通透性。使用ETDRS标准对数视力表测试视力。
22名患者自愿参与研究。初步检查后,因明显的玻璃体脱离/液化迹象排除了10名患者。9名玻璃体大致完整且有不同程度水肿的患者完成了交叉研究。AZM治疗使荧光素的渗透比降低了21%(P = 0.01),荧光素葡糖醛酸的渗透比降低了22%(P = 0.004)。在7名患者中测定了被动通透性和单向通透性。AZM使荧光素的被动通透性降低了27%(从1.1×10¹纳米/秒降至,P = 0.031),荧光素的单向通透性增加了95%(从1.2×10²纳米/秒升至,P = 0.047)。在7名患者中,有3名患者经荧光素血管造影测定,AZM导致黄斑水肿程度减轻。视力仅出现小幅改善(≤5个字母)。
本研究表明,AZM减轻水肿的作用是由于血视网膜屏障渗漏减少以及主动转运增强。